Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
John R TeerlinkRafael DiazG Michael FelkerJohn Joseph Valentine McMurrayMarco MetraScott D SolomonKirkwood F AdamsInder AnandAlexandra Arias-MendozaTor Biering-SørensenMichael BöhmDiana BondermanJohn G F ClelandRamon CorbalanMaria G Crespo-LeiroUlf DahlströmLuis E EcheverriaJames C FangGerasimos FilippatosCândida FonsecaEva GoncalvesovaAssen R GoudevJonathan G HowlettDavid E LanfearJing LiMayanna LundPeter MacdonaldViacheslav MareevShin-Ichi MomomuraEileen O'MearaAlexander ParkhomenkoPiotr PonikowskiFelix J A RamiresPranas SerpytisKaren SliwaJindrich SpinarThomas M SuterJanos TomcsanyiHans VandekerckhoveDragos VinereanuAdriaan A VoorsMehmet B YilmazFaiez ZannadLucie SharpstenJason C LeggClaire VarinNarimon HonarpourSiddique A AbbasiFady I MalikChristopher E Kurtznull nullPublished in: The New England journal of medicine (2020)
Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.).